The biotechnology company, mAbxience, specialises in the development of biosimilars, or to be precise, monoclonal antibodies. The organisation took part in the Astorga Science Week as a partner company at the event, proving its commitment to promoting biotechnology in the region.
Luisa Amoedo, Director of the León plant, took part in the talk on “Biotechnological Medicines: from León to the rest of the world”. During the session, she addressed the reality of the biopharmaceutical industry and reflected on the complexity of the main characteristics of biosimilars, as well as the role that mAbxience plays in the field.
In this regard, Amoedo talked about mAbxience’s commitment to promoting “the creation of highly-qualified positions of quality in the region, through business activities that provide a high added value to society as a whole”. Accordingly, she highlighted that in just one year, “the number of employees at mAbxience has increased from 10 to 62”, illustrating “the company’s rapid growth rate”. The plant Director also highlighted that mAbxience considers educating others on biosimilars to be of the utmost importance, “so that society as a whole understands the advantages that biosimilars entail for our national health services”.
Last October, mAbxience opened its Biosimilars Plant in León, which is the first plant in Spain to employ Single-Use technology dedicated to developing these medicines. Since mAbxience’s beginnings in 2009, the company has invested 115 million euros, representing one of the largest investments in a biotechnology project made by a Spanish multinational.